Compare Enveric Biosciences Inc (ENVB) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs JetBlue Airways Corporation — how do they compare? Enveric Biosciences Inc trades at $1.44 (market cap $6.80M), while JetBlue Airways Corporation trades at $3.86 (market cap $1.48B). The key difference: JetBlue Airways Corporation is far larger — about 217.6× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 30,275,693). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and JetBlue Airways Corporation for 44 Days on average.
| ENVB | JBLU | |
|---|---|---|
Market Cap | $6.80M | $1.48B |
Volume | 64,867 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $10.80 | $6.46 |
52-Week Low | $1.27 | $3.92 |
Typical Hold Time | 14 Days | 44 Days |
Enterprise Value | -$1.49M | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
JetBlue (JBLU) trades at $3.97, down 1.49% today, with a bearish technical outlook despite oversold RSI levels. The airline faces fundamental challenges with consecutive quarterly losses, negative profit margins (-9.32%), and elevated debt levels (debt-to-asset ratio of 51.28% in 2025). Recent developments include route expansion to Colombia and the launch of premium BlueFirst seating, but operational cash flow remains negative (-$94M in 2025).
The investment outlook is cautious given persistent losses and high leverage, though the current valuation (P/S 0.15, P/B 0.93) appears discounted. Analyst consensus is mixed with a $5.89 price target (48% upside) but predominantly Hold ratings (62%). Key risks include fuel cost volatility, competitive pressure, and macroeconomic sensitivity to travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
